Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Incannex Healthcare Ltd ADR (IXHL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/24/2025: IXHL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -82% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.73M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 57565 | Beta 1.92 | 52 Weeks Range 0.64 - 3.55 | Updated Date 04/2/2025 |
52 Weeks Range 0.64 - 3.55 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -33733.33% |
Management Effectiveness
Return on Assets (TTM) -82.35% | Return on Equity (TTM) -240% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20730792 | Price to Sales(TTM) 191.14 |
Enterprise Value 20730792 | Price to Sales(TTM) 191.14 | ||
Enterprise Value to Revenue 211.54 | Enterprise Value to EBITDA -5.13 | Shares Outstanding 27546800 | Shares Floating 13873064 |
Shares Outstanding 27546800 | Shares Floating 13873064 | ||
Percent Insiders 30.57 | Percent Institutions 1.25 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Incannex Healthcare Ltd ADR
Company Overview
History and Background
Incannex Healthcare Ltd ADR (IXHL) is an Australian-based clinical stage pharmaceutical company focused on developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs. Founded in 2015, Incannex has evolved from medicinal cannabis products to researching and developing psychedelic-assisted psychotherapy treatments.
Core Business Areas
- Medicinal Cannabis: Development of proprietary medicinal cannabis pharmaceutical products for conditions like obstructive sleep apnea (OSA) and inflammatory bowel disease (IBD).
- Psychedelic Medicine Therapies: Research and development of psychedelic medicine-assisted psychotherapy treatments for anxiety disorders, traumatic brain injury (TBI), and other mental health conditions.
Leadership and Structure
The leadership team includes Joel Latham (CEO) and Dr. Sud Agarwal (Chief Medical Officer). The company operates with a board of directors and various scientific advisory boards overseeing the development and clinical trials of its drug candidates.
Top Products and Market Share
Key Offerings
- IHL-42X: A proprietary medicinal cannabis formulation targeting obstructive sleep apnea. Clinical trials are underway. Competitors include traditional CPAP therapy and surgical interventions for OSA, as well as pharmaceutical approaches addressing daytime sleepiness associated with OSA.
- IHL-675A: A combination therapy (cannabidiol and hydroxychloroquine) designed to treat inflammatory bowel disease (IBD). Clinical trials ongoing. Competitors are standard IBD therapies such as biologics (Humira, Remicade) and corticosteroids.
- Psi-GAD: Psilocybin-assisted psychotherapy program for generalized anxiety disorder (GAD). Clinical trials in planning stages. Competitors include existing mental health providers and other companies in psilocybin-assisted therapy such as Compass Pathways (CMPS).
Market Dynamics
Industry Overview
The medicinal cannabis and psychedelic medicine industries are experiencing rapid growth, driven by increasing acceptance of these therapies for various medical conditions and evolving regulatory landscapes.
Positioning
Incannex Healthcare Ltd ADR is positioned as a clinical stage company focused on innovative treatments. Its competitive advantage lies in its proprietary formulations and combination therapies.
Total Addressable Market (TAM)
The TAM for medicinal cannabis and psychedelic therapies is projected to be in the billions of dollars. IXHL is positioned to capture a portion of this TAM through successful clinical trials and commercialization of its products.
Upturn SWOT Analysis
Strengths
- Proprietary formulations and unique combination therapies
- Experienced management team
- Focus on unmet medical needs
- Progressing clinical trials in multiple therapeutic areas
Weaknesses
- Clinical stage company with no currently marketed products
- Reliance on successful clinical trial outcomes and regulatory approvals
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
Opportunities
- Growing market for medicinal cannabis and psychedelic medicine
- Potential for partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new therapeutic areas
Threats
- Regulatory hurdles and changing regulations
- Competition from other pharmaceutical companies
- Failure of clinical trials
- Difficulty in securing funding
Competitors and Market Share
Key Competitors
- GWPH
- CRBP
- CMPS
- ATAI
Competitive Landscape
Incannex Healthcare Ltd ADR faces strong competition from established pharmaceutical companies and other emerging players in the medicinal cannabis and psychedelic medicine space. IXHL's focus on proprietary formulations could provide a competitive edge.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily in terms of pipeline expansion and clinical trial progress.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals, analyst estimates vary depending on trial success.
Recent Initiatives: Recent initiatives include advancing clinical trials for IHL-42X, IHL-675A, and Psi-GAD.
Summary
Incannex Healthcare is a clinical stage pharmaceutical company with innovative approaches in medicinal cannabis and psychedelic therapies, offering potential but also carrying inherent risks. Success depends heavily on positive clinical trial outcomes, regulatory approvals, and efficient financial management. With a focus on proprietary solutions, IXHL can distinguish itself if it navigates its clinical and regulatory hurdles successfully. The future will depend on its ability to raise capital and advance through clinical phases.
Similar Companies
ATAI
ATAI Life Sciences BV
ATAI
ATAI Life Sciences BV
CMPS
Compass Pathways Plc
CMPS
Compass Pathways Plc
CRBP
Corbus Pharmaceuticals Holding
CRBP
Corbus Pharmaceuticals Holding
Sources and Disclaimers
Data Sources:
- Incannex Healthcare Ltd ADR corporate website
- SEC filings
- Market research reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The data provided is based on publicly available information and analyst estimates, which are subject to change. Investing in pharmaceutical companies, especially those in early clinical stages, carries significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Incannex Healthcare Ltd ADR
Exchange NASDAQ | Headquaters Sydney, NSW, Australia | ||
IPO Launch date 2022-03-02 | President, CEO & Executive Director Mr. Joel Bradley Latham | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 9 | Website https://www.incannex.com |
Full time employees 9 | Website https://www.incannex.com | ||
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.